When MEKi was previously compared to the long-standing but limitedly proven cytostatic dacarbazine, only modest responses were observed in the treatment of NRAS-mutant melanoma9,53, and a clinical trial indicated that NRAS-mutant melanoma patients only show limited benefit to MEKi54. The gene discussed is NRAS; the disease is melanoma.